Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis
P. Horn, J. Norlin, K. Almholt, B. M. Viuff, E. D. Galsgaard, A. Hald, F. Zosel, H. Demuth, S. Poulsen, P. L. Norby, M. G. Rasch, M. Vyberg, M. P. Werge, L. L. Gluud, M. R. Rink, , P. N. Newsome
This study evaluates Gremlin-1 as a therapeutic target in MASH fibrosis, finding it upregulated but not amenable to targeting due to its restricted expression and lack of effect on fibrogenesis.
bioRxiv · Jan 3, 2024Pathology